Background
Aim
Material
Methods
Statistical analysis
Results
Feature | 30 patients with initial DCIS before local recurrence, number (percentage) | The same 30 patients after invasive breast cancer recurrence, number (percentage) | 11 patients without any recurrence, number (percentage) |
---|---|---|---|
Median age (range) | 56 (44–75) | 67 (48–83) | 54 (49–70) |
Median size of DCIS in mammography, (range) in mm | 14 (5–70) | 16 (2–30) | 13 (9–40) |
Estrogen receptor | |||
Positive | 23 (77) | 23 (77) | 8 (73) |
Negative | 7 (23) | 7 (23) | 3 (27) |
HER2 receptor | |||
Positive | 8 (27) | 7 (23) | 5 (45) |
Negative | 22 (73) | 23 (77) | 6 (55) |
Biological type | |||
HER2-positive ER/PgR-negative | 7 (24) | 5 (17) | 3 (27) |
HER2-positive ER/PgR-positive | 1 (3) | 2 (7) | 2 (18) |
Luminal A HER2-negative & | 15 (50) | 14 (47) | 4 (37) |
Luminal B HER2-negative# | 7 (23) | 8 (26) | 2 (18) |
Triple-negative | – | 1 (3) | – |
Type of detection | |||
Mammographically only | 29 (97) | 22(73) | 10 (90) |
Clinically | 1 (3) | 8 (27) | 1 (10) |
Histological grade | |||
G1 | 5 (17) | 4 (13) | 2 (18) |
G2 | 14 (46) | 16 (53) | 4 (37) |
G3 | 11 (37) | 10 (33) | 5 (45) |
Comedo necrosis | |||
Yes | 11 (37) | – | 5 (45) |
No | 19 (63) | 6 (55) | |
Median narrowest surgical margin (mm) | 5 (1–30) | – | 8 (1–10) |
Type of treatment | |||
Breast-conserving surgery* | 12 (40) | – | 8 (72) |
Breast-conserving treatment** | 15 (50) | 2 (7) | 3 (27) |
Mastectomy | 3 (10) | 28 (93) | 0 |
Adjuvant hormonal therapy | 0 | – | 0 |
Recurrence-free survival, median
(range) | – | 8 years (2–19) | – |
Localization of recurrence | |||
In tumor bed | 20 (67) | 20 (67) | – |
In the same quadrant up to 5 cm from tumor bed | 10 (33) | 10 (33) | – |
Presence of DCIS in invasive recurrence | |||
Yes | – | 4 (13) | – |
No | – | 26 (87) | – |
Lymph node metastases in invasive recurrence | |||
Yes | – | 2 (7) | – |
No | – | 28(93) | – |
Total stromal TILs’ infiltration (without division into CD4, CD8, etc.)
Initial scores of stromal TILs in 30 patients with initial DCIS before recurrence | Scores of stromal TILs in 30 patients after detection of invasive recurrence | Scores of stromal TILs in 11 patients without recurrence | |
---|---|---|---|
Median (range) | 10% (1–45) | 15% (2–70) | 8% (1–35) |
Scores of TILs depending on biological subtypes | |||
HER2-positive | 5% (1–25) | 5% (2–40) | 8% (1–35) |
Luminal HER2-negative | 7% (1–45) | 20% (5–70) | 10% (2–20) |
Scores of TILs depending on estrogen receptor | |||
ER-positive | 7% (1–45) | 20% (2–70) | 8% (2–25) |
ER-negative | 10% (1–25) | 5% (2–40) | 5% (1–35) |
Subsets of stromal cells
Type of immune cell | Initial scores of immune cells in 30 patients with initial DCIS before recurrence median (range) | Scores of immune cells in 30 patients after detection of invasive recurrence median (range) | p-value |
---|---|---|---|
CD20+ | 5% (1–30) | 17.5% (5–60) | < 0.001 |
CD 163+ | 1% (0–10) | 5% (0–20) | < 0.001 |
CD 138+ | 2% (0–30) | 5% (0–20) | 0.100 |
CD4+ | 1% (0–4) | 1% (0–4) | 0.483 |
CD8+ | 2% (1–10) | 2% (0–5) | 0.593 |
FOXP3+ | 0% (0–3) | 1% (0–3) | 0.439 |
TGF-Beta (percentage of patients with the positive reaction) | 30% | 80% | 0.426 |
Type of immune cell | Initial scores of immune cells in 30 patients with initial DCIS before recurrence median (range) | Scores of immune cells in 11 patients without recurrence median (range) | p-value |
---|---|---|---|
CD20+ | 5% (1–30) | 5% (1–15) | 0.942 |
CD 163+ | 1% (0–10) | 1% (0–3) | 0.942 |
CD 138+ | 2% (0–30) | < 1% (0–2)* | < 0.001 |
CD4+ | 1% (0–4) | 0% (0–2) | 0.287 |
CD8+ | 2% (1–10) | 1% (1–10) | 0.717 |
FOXP3+ | 0% (0–3) | 0% (0–1) | 0.513 |
TGF-Beta (percentage of patients with positive reaction) | 30% | 18% | 0.371 |
Type of immune cells | Thirty patients with the initial DCIS before recurrence (%) | Thirty patients after detection of invasive recurrence (%) | Eleven patients without recurrence (%) |
---|---|---|---|
CD20+ | 30/30 (100) | 30/30 (100) | 11/11 (100) |
CD163+ | 22/30 (73) | 26/30 (87) | 8/11 (73) |
CD138+ | 26/30 (87) | 30/30 (100) | 5/11 (45) |
CD4+ | 19/30 (63) | 23/30 (77) | 5/11 (45) |
CD8+ | 30/30 (100) | 27/30 (90) | 11/11 (100) |
FOXP3+ | 11/30 (37) | 20/30 (67) | 5/11 (45) |
TGF-beta | 9/30 (30) | 24/30 (80) | 2/11 (18) |